P1069: Impact of Unmet Needs on Quality of Life in Patients with Short Bowel Syndrome in JapanECCO'25Year: 2025
Authors: Ogino, T.(1)*;Watanabe, K.(2);Nakano, H.(3);Hayashi, A.(3);
(1)Graduate School of Medicine- Osaka University, Department of Gastroenterological Surgery, Suita, Japan;(2)Tohoku University Graduate School of Medicine, Department of Surgery, Sendai, Japan;(3)Takeda Pharmaceutical Company Limited, Japan Medical Office, Tokyo, Japan;
P1070: Comaparison of Effectiveness and Perisitence Anti-TNF drugs on Perianal Fistulizing Crohn's Disease: A Single Tertiary IBD Referral Center ExperienceECCO'25Year: 2025
Authors: Koç, Ö.(1)*;Acehan, M.F.(1);Yılmaz, V.(1);Guvenir, S.T.(1);Toruner, M.(2);
(1)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;(2)Ankara University Medical School- Ibni-sina Hospital, Department of Gastroenterology, Ankara, Turkey;
P1071: Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 studyECCO'25Year: 2025
Authors: Schreiber , S.W.(1);Clemow , D.B.(2);Keohane , A.(3);Zhu , B.(2);Ritter , T.(4)*;Regueiro , M.(5);Hudesman , D.(6);Chen , Y.F.(2);Owen , C.(2);
(1)University Hospital Schleswig-Holstein- Christian-Albrecht University of Kiel, Department of Internal Medicine, Kiel, Germany;(2)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(3)HaaPACS GmbH, Statistics, Schriesheim, Germany;(4)GI Alliance Research, Department of Research and Education, Southlake, United States;(5)Cleveland Clinic Foundation, Department of Gastroenterology- Hepatology- and Nutrition, Cleveland, United States;(6)New York University NYU Langone Health, Department of Medicine- Division of Gastroenterology, New York, United States;
1. D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. Erratum in: N Engl J Med. 2023 Aug 24;389(8):772. doi: 10.1056/NEJMx230004.
P1072: The influence of anxiety and depression and the online mindfulness interventions on the quality of life among patients with Inflammatory Bowel Disease (IBD) : Web-Based Survey StudyECCO'25Year: 2025
Authors: Hu, S.(1)*; Xu, D.(1);Zhu, C.(1);Wang, Y.(1);Li, S.(2); Chen, Y.(1);Chen, Y.(3);Wang, C.(1);
(1)the Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(2)the Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Nursing, Hangzhou, China;(3)the Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Psychiatry, Hanzghou, China;
P1073: Clinical characteristics and outcomes of patients with Inflammatory Bowel Disease under long term (>10years) anti-TNFa treatmentECCO'25Year: 2025
Authors: Orfanoudaki, E.(1)*;Foteinogiannopoulou, K.(1);Theodoraki, E.(1);Drygiannakis, I.(1);Panayiotou, S.(1);Papatzelou, I.(1);Koutroubakis, I.(1);
(1)University Hospital of Heraklion, Gastroenterology, Heraklion, Greece;
P1074: Deep dive into an IBD service: mapping and identifying service gapsECCO'25Year: 2025
Authors: Kemp, K.(1)*;Cornick, S.(2);Howard, W.(2);Oven, D.(2);Puleston, J.(2);Gordon, D.(3);
(1)Manchester University NHS Foundation Trust / University of Manchester, gastroenterology, manchester, United Kingdom;(2)Manchester University NHS Foundation Trust, Gastroenterology, manchester, United Kingdom;(3)NHS Greater Manchester, Elective recovery and reform, manchester, United Kingdom;
Alison Leary, Isobel Mason, Geoffrey Punshon, 'Modelling the Inflammatory Bowel Disease Specialist Nurse Workforce Standards by Determination of Optimum Caseloads in the UK' Journal of Crohn's and Colitis, Volume 12, Issue 11, November 2018, Pages 1295–1301, https://doi.org/10.1093/ecco-jcc/jjy106
P1075: Evaluation of characteristics of faecal urgency in patients with ulcerative colitisECCO'25Year: 2025
Authors: Ivány, E.(1)*;Bacsur, P.(1);Horvát, B.(1);Farkas, B.(1);Bálint, A.(1);Rutka, M.(1);Fábián, A.(1);Bősze, Z.(1);Farkas, K.(1);Szepes, Z.(1);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical Centre- University of Szeged, Department of Internal Medicine- Center for Gastroenterology, Szeged, Hungary;
P1076: Improvement of Work Productivity and Activity Impairment (WPAI) in patients with moderate to severe UC using Biologics therapy; the MOSAIK cohort studyECCO'25Year: 2025
Authors: Seong, G.(1)*;Park, Y.(2);Lee, K.M.(3);Jung, S.A.(2);Park, Y.S.(1);
(1)Nowon Eulji Hospital- Eulji University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(2)Ewha Womans University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(3)St. Vincent's Hospital- The Catholic University of Korea College of Medicine, Internal Medicine, Suwon, Korea- Republic Of;
1. A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study. Intest Res. 2019;17(1):1-5. Published online January 25, 2019
P1077: Early detection of non-response to non-anti-TNF treatment in Inflammatory Bowel Disease patients using neutrophil-to-lymphocyte ratio as a biomarkerECCO'25Year: 2025
Authors: Rellou, S.(1)*;Kordalis, L.(2);Spyrantis , A.(1);Lamprou, S.(1);Efstathiou, S.(1);Pagoni, A.(1);Manou, D.(1);Sdonas, T.(1);Tasovasili, A.(1);
(1)General Oncology Hospital of Kifisia "Agioi Anargyroi", Gastroenterology Department, Athens, Greece;(2)National Kapodistrian University of Athens, Department of Mathematics, Athens, Greece;
1.Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med. 2021;10(18):4219. Published 2021 Sep 17. doi:10.3390/jcm10184219
2. Qian G, Hongxia D, Jin LI. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(4):453-458. doi:10.12122/j.issn.1673-4254.2020.04.01
P1078: Weight-loss medications and bariatric surgery are infrequently used in obese patients with inflammatory bowel disease in North and East Devon in the United Kingdom (UK)ECCO'25Year: 2025
Authors: Hodges, P.(1)*;Roberts, C.(1);Badrulhsisham, F.(1);Pamment, D.(1);Smith, R.(1);Cairnes, V.(1);Bewshea, C.(1);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1);
(1)Royal Devon University Healthcare NHS Trust, Gastroenterology, Exeter, United Kingdom;
P1080: Early Biologic Therapy for Inflammatory Bowel Disease in Taiwan: A Single- Center Retrospective Cohort StudyECCO'25Year: 2025
Authors: Wong, T.C.(1)*;Liao, C.Y.(1);Lee, C.Y.(1);Lin, W.C.(1);Chang, C.W.(1,2,3);Chen, M.J.(1,2,3);Chang, C.W.(1,2,3);
(1)MacKay Memorial Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Taipei, Taiwan;(2)MacKay Medical College, Department of Medicine, New Taipei City, Taiwan;(3)MacKay Junior College of Medicine, Nursing and Management, New Taipei City, Taiwan;
P1081: Correlation of vedolizumab levels with medium-and long-term response in patients with Inflammatory Bowel Disease.ECCO'25Year: 2025
Authors: Hernández-Pérez, M.(1);Suarez Ferrer, C.J.(2,3)*;García-Ramírez, L.(2,3);Martín‑Arranz, E.(2,3);Sánchez‑Azofra, M.(2,3);Poza Cordón, J.(2,3);Rueda García, J.L.(2,3);Martín-Arranz, M.D.(2,3,4);
(1)Principe de Asturias University Hospital, Gastroenterology Department, Alcalá de Henares, Spain;(2)La Paz University Hospital, Gastroenterology Department. IBD Unit, Madrid, Spain;(3)La Paz University Hospital, Hospital La Paz Institute for Health Research, Madrid, Spain;(4)Universidad Autónoma, Faculty of Medicine, Madrid, Spain;
1. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol [Internet]. 2021 May 1 [cited 2024 Oct 21];116(5):1007–14. Available from: https://pubmed.ncbi.nlm.nih.gov/33929379/2.
2. Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, et al. Therapeutic Drug Monitoring of Biologics during Induction to Prevent Primary Non-Response. J Crohns Colitis. 2020;14(4):543–56.
3. Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, et al. Deep Remission with Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019;13(2):172–81.
4. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202
P1082: Is mutiple switching between infliximab biosimilars safe in iInflammatory Bowel Disease?ECCO'25Year: 2025
Authors: Karataş, A.(1);Kirman, D.(1)*;Demir, B.(1);Karakan, T.(1);
(1)Gazi University, Gastroenterology&Hepatology, Ankara, Turkey;
1. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–60. 2. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biol J Int Assoc Biol Stand. 2014 Jul;42(4):177–83. 3. Hanzel J, Jansen JM, Ter Steege RWF, Gecse KB, D’Haens GR. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis. 2022 Mar;28(4):495–501. 4. Taherzadeh N, Kataery D, Murray C, Shah T. PMO-33 Infliximab biosimilar switching – can you switch more than once? Vol. 70, Gut. 2021. A93.3-A94.
P1083: Biological therapy and histological tumor necrosis factor - alpha expression in Inflammatory Bowel Disease patientsECCO'25Year: 2025
Authors: Bertani, A.(1)*;Pecchini, M.(1);Lami, F.(1);Reggiani Bonetti , L.(2);Caramaschi, S.(2);Colecchia, A.(1);
(1)University Hospital of Modena, Gastroenterology Unit, Modena, Italy;(2)University Hospital of Modena, Pathology Istitute, Modena, Italy;
Villanacci V et al "Histopathology of inlammatory bowel disease- Position statement of the Pathologists of the Italian Group of the Study of the Inflammatory Bowel Disease (IG- IBD) and Italian Group of Gastrointestinal Pathologists (GIPAD-SIAPEC) " Digestive ad Liver Disease 2020
Daperno et al . "Development and validation of a new, simplified endoscopic activity score of Crohn's Disease: the SES - CD" GIE 2002
P1084: Safety of tofacitinib and upadacitinib compared to other advanced therapies in ulcerative colitis: a large real-world comparison.ECCO'25Year: 2025
Authors: Fiorino, G.(1)*;Allocca, M.(2);D'Amico, F.(2);Rusconi, F.(3);Hernandez, G.(3);Zilli, A.(2);Parigi, T.(2);Furfaro, F.(2);Cosintino, R.(1);Faggiani, R.(1);Jairath, V.(4);Peyrin-Biroulet, L.(5);Danese, S.(2);
(1)San Camillo-Forlanini Hospital, IBD Unit- Department of Gastroenterology and Digestive Endoscopy, Rome, Italy;(2)San Raffaele Hospital and Vita e Salute San Raffaele University, Gastroenterology and Digestive Endoscopy, Milan, Italy;(3)TriNetX, TriNetX, Cambridge- MA, United States;(4)Western University, Department of Medicine- Division of Gastroenterology- Department of Epidemiology and Biostatistics, London- Ontario, Canada;(5)University Hospital of Nancy, INFINY Institute, Vandoeuvre Les Nancy, France;
1. European Medicine Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2022 [cited 2024 Jun 12]; Available from: https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders.
P1085: Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UCECCO'25Year: 2025
Authors: Peyrin-Biroulet, L.(1)*;Yen, M.(2);Zhou, W.(2);Dong, B.(2);Danese, S.(3);Feagan, B.G.(4);Sands, B.E.(5);
(1)INFINY Institute- INSERM NGERE- Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(2)Merck & Co.- Inc., Merck Research Laboratories, Rahway- New Jersey, United States;(3)IRCCS San Raffaele Scientific Institute- Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(4)Western University, Departments of Medicine- Epidemiology- and Biostatistics, London, Canada;(5)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- NY, United States;
1. Sands BE, et al. N Engl J Med 2024;391:1119-29.
P1086: Achieving early symptom resolution and endoscopic outcomes is associated with improved long-term outcomes in ulcerative colitis: A post-hoc analysis of INSPIRE and COMMAND studiesECCO'25Year: 2025
Authors: Tinoco da Silva Torres, J.(1,2,3)*;Danese, S.(4);Tanida, S.(5);Dulai, P.S.(6);Xuan, S.(7);Kalabic, J.(8);Morisset, P.(7);Vladea, R.(7);Sharma, D.(7);Panes, J.(9);
(1)Hospital Beatriz Ângelo, Gastroenterology Division, Loures, Portugal;(2)Hospital da Luz, Gastroenterology Division, Lisbon, Portugal;(3)Universidade de Lisboa, Faculdade de Medicina, Lisbon, Portugal;(4)IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(5)Nagoya City University Graduate School of Medical Sciences, Education and Research Center for Community Medicine-, Nagoya, Japan;(6)Northwestern University, Department of Medicine- Division of Gastroenterology and Hepatology, Chicago, United States;(7)AbbVie Inc., Gastroenterology, Chicago, United States;(8)AbbVie Deutschland GmbH & Co. KG-, Gastroenterology, Ludwigshafen, Germany;(9)CIBERehd, Hospital Clínic Barcelona- IDIBAPS, Barcelona, Spain;
1. Solitano V, et al. J Clin Med. 2020;9(8):2646.
P1087: Opioid Use Before and After Ulcerative Colitis Diagnosis: A Nationwide Cohort Study in Sweden 2006-2021ECCO'25Year: 2025
Authors: Osooli, M.(1)*;Voghera, S.(1);Bruze, G.(1);Nordenvall, C.(2,3);Myrelid, P.(4,5);Everhov, Å.H.(1,6);Ludvigsson, J.F.(7,8);Olén, O.(1,6,9);
(1)Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden;(2)Karolinska University Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden;(3)Karolinska University Hospital, Department of Pelvic Cancer- Unit of IBD-surgery, Stockholm, Sweden;(4)Linköping University Hospital, Department of Surgery, Linköping, Sweden;(5)Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden;(6)Karolinska Institutet, Department of Clinical Science and Education Södersjukhuset, Stockholm, Sweden;(7)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(8)Örebro University Hospital, Department of Pediatric, Örebro, Sweden;(9)Stockholm South General Hospital, Sachs’ Children and Youth Hospital, Stockholm, Sweden;
1. Scholl, L., et al., Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep, 2018. 67(5152): p. 1419-1427.
2. Niccum, B., et al., Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2021. 19(5): p. 895-907 e4.
P1088: Positive effects of a mindfulness-based intervention on depression, stress and perceived control, but not on disability in patients with Crohn’s disease: results from a randomized controlled trialECCO'25Year: 2025
Authors: Keersmaekers, B.(1)*;Beeckmans, D.(1);Brams, S.(1);Vanderbist, K.(1);Van den Bosch, M.(2);Vermeire, S.(1);Verstockt, B.(1);Sabino, J.(1);Van Diest, I.(3);Ferrante, M.(1);
(1)University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Leuven Mindfulness Center, Leuven, Belgium;(3)KU Leuven, Research Group Health Psychology, Leuven, Belgium;
